NATURALE-POC
Bridging the gap in nanoparticle-based enzyme biosensing
| Coordinatore | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 165˙889 € |
| EC contributo | 147˙918 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2011-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-04-01 - 2014-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | hostInstitution | 147˙918.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'There is growing commercial interest in bio-responsive materials because of their many applications, such as in medical diagnostics at the point of care and in drug discovery and development. Our developed assay technologies manipulate the properties of gold nanoparticles and enzyme-based reactions to detect enzyme activity. Most diagnostics target either expressed antigens (immunodiagnostics) or DNA (molecular diagnostics). Our bio-responsive nanoparticle technology can offer a sensitive, specific and affordable platform for the development of rapid point-of-care tests based on simple colour readouts. Additionally one of the great advantages of our technology is the fact that, in addition to diagnosing disease, it can also potentially help in the search for new drugs to treat those diseases. In contrast to methods that simply measure enzyme concentration, our method actually measures enzyme activity. In this ERC POC our expected outcomes include a number of important commercial milestones and technical developments to expand the platform to other diseases and test its application in high throughput drug screening. This value will carry through in both licensing and spin-out, since these issues are fundamental to any business venture. Furthermore, we propose a balanced plan that includes technical research combined with commercial investigations and identification of appropriate industrial partners. At the conclusion of this work, we will be in a much stronger position to immediately commercialise this technology, bringing its benefits to the broader healthcare market.'